SLGL Description — Sol-Gel Technologies Ltd
Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Co.'s primary product candidate, Twyneo®, is a once-daily, non-antibiotic topical cream that it is developing for the treatment of acne vulgaris. Co.'s second branded product candidate is Epsolay®, a potential treatment for subtype II rosacea. Co.'s other branded product candidates are SGT-210, a potential treatment of palmoplantar keratoderma. Co. is also pre-clinically testing erlotinib, tapinarof and roflumilast in various new pharmaceutical indications.
|
Free SLGL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|